Urinary pH is highly associated with tumor recurrence during intravesical mitomycin c therapy for nonmuscle invasive bladder tumor

Journal of Urology

Volumn 185, Issue 3, 2011, Pages 802-806

  Maeda, Takahiro ^a   Kikuchi, Eiji ^a   Matsumoto, Kazuhiro ^a   Miyajima, Akira ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

carcinoma; local; mitomycin; neoplasm recurrence; urinary bladder; urothelium

Indexed keywords

MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DYSURIA; EPIDIDYMITIS; FATIGUE; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NONMUSCLE INVASIVE BLADDER TUMOR; PAIN; PATHOLOGY; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT DISEASE; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; UNIVERSITY HOSPITAL; URINARY FREQUENCY; URINE PH;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 79851514685     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.10.081     Document Type: Article

References (24)

1. D.S. Kaufman, W.U. Shipley, and A.S. Feldman Bladder cancer Lancet 374 2009 239
2. K.A. David, K. Mallin, and M.I. Milowsky Surveillance of urothelial carcinoma: stage and grade migration, 19932005 and survival trends, 19932000 Cancer 115 2009 1435
3. B.W. Van Rhijn, M. Burger, and Y. Lotan Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 2009 430
4. D.L. Lamm BCG immunotherapy for transitional-cell carcinoma in situ of the bladder Oncology 9 1995 947
5. M.S. Cookson, and M.F. Sarosdy Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy J Urol 148 1992 797
6. S. Krege, G. Giani, and R. Meyer A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin J Urol 156 1996 962
7. M. Huncharek, and B. Kupelnick The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a meta-analytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy Am J Clin Oncol 27 2004 522
8. T. Takeda, E. Kikuchi, and K. Yuge Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence Urology 73 2009 1318
9. K. Sasaki, M. Yokoyama, and M. Kanemura Adverse effects of intravesical bacillus Calmette-Guerin instillation for superficial bladder cancer J Annu Soc BCG and BRM Immunother 20 1996 89
10. M. Colombel, F. Saint, and D. Chopin The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study J Urol 176 2006 935
11. M.C. Hall, S.S. Chang, and G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
12. J.L. Au, R.A. Badalament, and M.G. Wientjes Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial J Natl Cancer Inst 93 2001 597
13. M.D. Shelley, J.B. Court, and H. Kynaston Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer Cochrane Database Syst Rev 3 2003 CD03231
14. P.K. Madhusudan, A.S. Michael, and S.S. Mark Complication of intravesical therapy for urothelial cancer of the bladder J Urol 175 2006 2004
15. T.D. Schmittgen, M.G. Wientjes, and R.A. Badalament Pharmacodynamics of mitomycin C in cultured human bladder tumors Cancer Res 51 1991 3849
16. M.G. Wientjes, R.A. Badalament, and J.L. Au Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer Cancer Chemother Pharmacol 32 1993 255
17. J.T. Dalton, M.G. Wientjes, and R.A. Badalament Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients Cancer Res 51 1991 5144
18. Z. Shen, T. Shen, and M.G. Wientjes Intravesical treatment of bladder cancer: review Pharmaceut Res 25 2008 1500
19. E. Michael, M.A. Harrison, and E.B. David Utility of oral dissolution therapy in the management of referred patients with secondary treated uric acid stones Urology 59 2002 206
20. S.M. Di Stasi, A. Giannantoni, and R.L. Stephen Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study J Urol 170 2003 777
21. R. Colombo, L.F. Da Pozzo, and A. Salonia Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma J Clin Oncol 21 2003 4270
22. A.G. Heijden, P.M. Moonen, and E.B. Cornel Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response J Urol 176 2006 1349
23. P.U. Malmstrom, H. Wijkstrome, and C. Lundholm 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma J Urol 161 1999 1124
24. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124